News | January 26, 2024
Astec LifeSciences posts Q3 FY24 consolidated loss at Rs. 24.33 Cr
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
Eris Lifesciences enters into term loan agreement with Citi Bank
The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
